论文信息 - High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy. - 字舞流文

High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy.

C. la Vecchia | S. Franceschi | M. D’Incalci | C. Mangioni

[1] D. Guthrie. THE TREATMENT OF ADVANCED CYSTADENOCARCINOMA OF THE OVARY WITH GESTRONOL AND CONTINUOUS ORAL CYCLOPHOSPHAMIDE , 1979, British journal of obstetrics and gynaecology.

[2] K. M. Kelly,et al. Estrogen and Progestin Binding in Cytosols of Ovarian Adenocarcinomas , 1979, Obstetrics and gynecology.

[3] J. Edmonson,et al. Medroxyprogesterone acetate for the treatment of metastatic and recurrent ovarian carcinoma. , 1977, Cancer treatment reports.

[4] D. Decker,et al. 6-Dehydro-6,17 alpha-dimethylprogesterone (NSC-123018) for the treatment of metastatic and recurrent ovarian carcinoma. , 1973, Cancer chemotherapy reports.

[5] H. Ward. PROGESTOGEN THERAPY FOR OVARIAN CARCINOMA , 1972, The Journal of obstetrics and gynaecology of the British Commonwealth.

[6] A. Varga,et al. Effect of 17‐alpha-Hydroxyprogesterone 17‐n‐caproate on Various Pelvic Malignancies , 1964, Obstetrics and gynecology.

[7] B. Jolles. Progesterone in the Treatment of Advanced Malignant Tumours of Breast, Ovary and Uterus , 1962, British Journal of Cancer.